Deals In Depth: December 2013
Following the loss of patent protection on its antidepressant Lexapro in 2012, Forest added a new drug to its neurology portfolio, licensing US rights to Merck’s antipsychotic Saphris for $240 million; AstraZeneca took full control of BMS’s global diabetes business, paying $2.9 billion up front. Financing in December lagged behind the previous month’s figures in both biopharma and device.
You may also be interested in...
Can "real world evidence" drive consumer health innovation? HBW Insight speaks to Orbital Research’s Chris Bunniss about RWE’s potential for the OTC industry.
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Italy's Chiesi is looking to take a slice of Poland's consumer healthcare market by acquiring infant supplements specialist Smart Pharma.